Hormonal
Diabetes mellitus is an independent major risk factor for cardiovascular disease (CVD), and from a cardiovascular medicine perspective, it is appropriate to classify diabetes itself as a cardiovascular disease.
If you have diabetes, you must treat your cardiovascular health with the same urgency as your blood sugar. Diabetes is not just a metabolic issue; it is a direct cause of heart attacks, strokes, and heart failure. Aggressive management of blood pressure, cholesterol, and smoking cessation is mandatory because your baseline risk for heart disease is already significantly elevated by the diabetes itself.
These considerations have convinced the Scientific Advisory and Coordinating Committee of the American Heart Association (AHA) that diabetes mellitus deserves to be designated a major risk factor for CVD... it may be appropriate to say, 'diabetes is a cardiovascular disease.'
Why this rating
Based on a comprehensive AHA Scientific Statement reviewing large epidemiological, pathological, and clinical trial data.
Source
Diabetes and Cardiovascular Disease
Scott M. Grundy et al. · Circulation · 1999
DOI 10.1161/01.cir.100.10.1134
More from this paper
- Insulin resistance is a multisystem disorder that predisposes individuals to both cardiovascular disease and type 2 diabetes, often manifesting as the metabolic syndrome (abdominal obesity, atherogenic dyslipidemia, hypertension, glucose intolerance, and prothrombotic state).Strong
- Aggressive LDL-lowering therapy reduces recurrent coronary heart disease (CHD) events in patients with diabetes, even if their baseline LDL cholesterol is not markedly elevated.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →